Heghine Khachatryan/Linkedin
Aug 5, 2025, 02:28
Personalized Perioperative Management in Hemophilia: Key Insights from Heghine Khachatryan
Heghine Khachatryan, Head of Hemophilia and Thrombosis Center, Yeolyan Hematology and Oncology Center, recently shared a post on X:
“Individualized perioperative management based on FVIII/IX baseline levels and inhibitor status
•Algorithmic approach to factor replacement depending on BU levels and recovery response
•Adaptations for Emicizumab-treated patients and low-resource settings”
Stay informed with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia